<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666809</url>
  </required_header>
  <id_info>
    <org_study_id>12049</org_study_id>
    <secondary_id>2006-000463-29</secondary_id>
    <nct_id>NCT00666809</nct_id>
  </id_info>
  <brief_title>Vardenafil in Tinnitus</brief_title>
  <official_title>Evaluation of Vardenafil for the Treatment of Subjective Tinnitus: A Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is incidental evidence (casuistic findings) that the treatment with vardenafil of male
      patients suffering from erectile dysfunction and comorbid tinnitus experienced an improvement
      of their tinnitus.

      Randomized, parallel-group, double-blind, placebo-controlled trial over 16 weeks (12 weeks of
      treatment + 4 weeks follow-up) with 10 mg vardenafil BID p.o. in men and women with chronic
      tinnitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total score of the Tinnitus</measure>
    <time_frame>4 times in 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Audiometric measurements (mode, frequency and loudness of tinnitus, pure tone audiogram, speech audiogram)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF 36 Questionnaire)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum human chorionic Gonadotropin (hcG), pregnancy test</measure>
    <time_frame>once at screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levitra (Vardenafil, BAY38-9456)</intervention_name>
    <description>Vardenafil 10 mg BID p.o. for 12 weeks + 4 weeks follow-up</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo BID p.o. for 12 weeks + 4 weeks follow-up</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic subjective cochlear tinnitus

          -  No treatment of tinnitus within 4 weeks prior to study entry

          -  Duration of tinnitus &gt; 3 months

        Exclusion Criteria:

          -  Acute tinnitus

          -  Intermittent tinnitus

          -  History of M. Menier√©

          -  History of conductive deafness

          -  History of psychogenic deafness

          -  History of tumors of the middle ear, inner ear or cerebella-pontine angle (malignant
             and non malignant)

          -  Patients diagnosed of multiple sclerosis

          -  History of myocardial infarction, stroke, or life-threatening arrhythmia within the
             prior 6 months

          -  Nitrates or nitric oxide donors

          -  Any other concurrent treatment of tinnitus during study

          -  pregnant and breast-feeding women

          -  women with child-bearing potential not using adequate birth control method (Note: as
             adequate method of birth control oral contraception, spiral or sexual abstinence is
             recommended)

          -  Other exclusion criteria apply according to the Summary of Product Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <state>Berlin / 285</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here and search for websynopsis result of Bayer Products</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu</url>
    <description>click here and search for Bayer product information provided by the EMA</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vardenafil,</keyword>
  <keyword>Tinnitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

